ClinicalTrials.gg
CompletedNCT03774082REACH 5Updated Dec 11, 2025Results posted

Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant

A Phase 2 interventional study of INC424 in Graft vs Host Disease, sponsored by Novartis Pharmaceuticals. Completed at 21 sites in 14 countries. Open to participants aged 28 Days to 17 Years. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
28 Days to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ruxolitinib in Graft vs Host Disease — 13 open to participants now, 16 under way, 2 of them phase 3. ruxolitinib · Graft vs Host Disease.

Enrollment
17th of 27
46 · median 54
Started
2020
with 1 other
Phase 2
13 of 27
6 open now
Registered
9th of 27
by date
Lead sponsor
6 of 27
Novartis Pharmaceuticals

Among the 27 studies testing ruxolitinib in Graft vs Host Disease, this one is the 17th largest by enrollment, is one of 2 that started in 2020, is one of 13 in phase 2, and was the 9th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

13 of the 27 studies testing ruxolitinib in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 28 Days to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ruxolitinib in Graft vs Host Disease, or all of them as a file.
02

Study summary

This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children, and adolescents aged ≥28 days to \<18 years old with either moderate to severe treatment-naive cGvHD or SR-cGvHD.

Although 46 participants were enrolled,1 participant (enrolled in the ≥6y to \<12y age group) received study treatment beyond protocol requirements and was excluded from analyses.

Read the detailed description

Subjects were grouped according to their age as follows:

  • Group 1 included subjects ≥12y to \<18y
  • Group 2 included subjects ≥6y to \<12y
  • Group 3 included subjects ≥2y to \<6y and
  • Group 4 included subjects ≥28days to \<2y. Enrollment initiation into the youngest age group, Group 4, was subject to the availability of data in this age group from another study, as well as a review of available PK, safety, and activity data generated from Groups 1 to 3 in the current study. At least 5 evaluable participants per group were needed for the primary analysis in Groups 1, 2 and 3. No minimum number of evaluable participants were needed in Group 4. Enrollment was completed prior to the availability of the data and so no subjects were enrolled in Group 4.

After a screening period of Day -28 to Day -1: eligible subjects started study treatment on Cycle

1 Day 1 and were treated for up to a maximum of 3 years (39 cycles/156 weeks) or until early discontinuation. Subjects who discontinued study treatment for any reason earlier than 39 cycles were followed every 6 months until 3 years from their first dose of study treatment was reached.

03

Conditions studied

  • Graft vs Host Disease

Keywords

  • GvHD
  • INC424
  • pediatric
  • Chronic Graft versus Host Disease
  • moderate and severe chronic graft vs. host disease
  • allogeneic stem cell transplant
  • ruxolitinib
  • corticosteroids
04

Who can participate

Ages eligible
28 Days to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects age ≥28 days and \<18 years at the time of .
  • Subjects who have undergone a successful alloSCT from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood. Recipients of myeloablative or reduced intensity conditioning are eligible.
  • Subjects with diagnosed moderate to severe cGvHD according to NIH 2014 Consensus Criteria prior to Cycle 1 Day 1. Other possible diagnoses for clinical symptoms supporting cGvHD diagnoses must be excluded (e.g., infection, drug side effects, ). Subjects must be either:

    • Treatment-naive cGvHD subjects that have not received any prior systemic treatment for cGvHD except for a maximum 72h of prior systemic therapy of methylprednisolone or equivalent after the onset of chronic GvHD. Subjects are allowed to have received prior systemic treatment for cGvHD prophylaxis (as long as the prophylaxis was started prior to the diagnosis of cGvHD).

OR o Steroid- moderate to severe cGvHD as per institutional criteria, or per physician decision in case institutional criteria are not available, and still receiving systemic corticosteroids for the treatment of cGvHD for a duration of \<18 months prior to Cycle 1 Day 1. In case the corticosteroids were previously interrupted due to response, the duration of \< 18 months applies to the last period of corticosteroid use.

Exclusion criteria

Exclusion Criteria:

  • SR-cGvHD subjects with a prior cGvHD treatment with a JAK1- or a JAK2- or a JAK1/2-inhibitor, except when the subject achieved complete or partial response and has been off JAK inhibitor treatment for at least 4 weeks prior to Cycle Day 1 or up to 5 times the half-life of the prior JAK inhibitor, whichever is longer.

    * Subjects who initiated systemic calcineurin inhibitors (CNI; cyclosporine or tacrolimus) within 3 weeks prior to start of ruxolitinib on Cycle 1 Day 1. Note: systemic CNI are allowed when initiated > 3 weeks from start of ruxolitinib.

  • Failed prior alloSCT within the past 6 months
  • Significant respiratory disease including subjects who are on mechanical ventilation or who have a resting oxygen saturation \< 90% by pulse-oximetry on room-air.
  • Impairment of gastrointestinal (GI) function (unrelated to GvHD) or GI disease (unrelated to GvHD) that may significantly alter the absorption of oral ruxolitinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection),
  • Cholestatic disorders, or unresolved sinusoidal obstructive syndrome/veno-occlusive disease of the liver (defined as persistent abnormalities not attributable to cGvHD and ongoing organ dysfunction)
  • Presence of clinically active uncontrolled infection including significant bacterial, fungal, viral or parasitic infection requiring treatment.
  • Known (HIV) infection.
  • Evidence of uncontrolled virus (HBV) or virus (HCV) based on assessment done by Investigator or delegate.
  • Known allergies, , or intolerance to any of the study medications, , or similar compounds.
  • History of bone disorders such as osteogenesis imperfecta, rickets, renal osteodystrophy, osteomyelitis, osteopenia, fibrous dysplasia, osteomalacia etc. prior to the underlying diagnosis which resulted in the alloSCT.
  • History of endocrine or kidney related growth retardation prior to the underlying diagnosis which resulted in the alloSCT.
  • Evidence of clinically active tuberculosis (clinical diagnosis per local practice)
  • Any therapy for indications other than cGvHD at doses > 1 mg/kg/daymethylprednisolone (or equivalent prednisone dose 1.25 mg/kg/day) within 7 days of the screening visit.
  • History of progressive multifocal leuko-encephalopathy (PML).
  • Presence of severely impaired renal function
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    INC424 (ruxolitinib)

    All pediatric participants received ruxolitinib twice a day (BID) in either tablet or oral solution (liquid), depending on the group they were in.

    Drug: INC424

Interventions

  • DrugINC424

    Ruxolitinib was taken orally based on age groups as follows: Group 1 (\>=12y to \<18y): 10mg bid as tablet Group 2 (\>=6y to \<12y): 5mg bid as tablet or liquid Group 3 (\>=2y to \<6y): 4mg/m2 bid as liquid

    Also known as: Ruxolitinib

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) at Cycle 7 Day 1

    ORR is defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response. The response is assessed per National Institute of Health (NIH) consensus criteria and scoring of response was relative to the organ stage at the start of study treatment.

    Time frame: At Cycle 7 Day 1 (Day 168); Cycle = 28 Days

Secondary outcomes

  1. Ruxolitinib Concentrations by Timepoint

    Pharmacokinetics (PK) of ruxolitinib by age groups (and formulation tablet vs liquid).

    Time frame: Cycle 1 Day 1: 0.5, 2 and 6 hours post-dose; Pre-dose on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 22, Cycle 3 Day 1, Cycle 5 Day 1 and Cycle 7 Day 1; Cycle = 28 Days

  2. Duration of Response (DOR)

    Time from first response until chronic Graft vs. host disease (cGvHD) progression, death, or the date of addition of systemic therapies for cGvHD assessed for responders only based on BOR up to Cycle 7 Day 1. Presented as percentage of participants to still be in response at different time points in months (per Kaplan-Meier estimates). Participants without event will be censored at the date of their last response assessment prior to or at the analysis cut-off date if no events occurred on or before 12 weeks (84 days) after the last GvHD assessment. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

    Time frame: From baseline up to 39 cycles; Cycle = 28 Days

  3. Overall Response Rate (ORR) at Cycle 4 Day 1

    ORR is defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response. The response is assessed per National Institute of Health (NIH) consensus criteria and scoring of response will be relative to the organ stage at the start of study treatment at Cycle 4 Day 1.

    Time frame: At Cycle 4 Day 1 (Day 84); Cycle = 28 Days

  4. Best Overall Response (BOR)

    Percentage of participants who achieved overall response (complete response (CR) or partial response (PR)) at any time point until Cycle 7 Day 1 or the start of additional systemic therapy for chronic GvHD.

    Time frame: Until Cycle 7 Day 1 (Day 168) or the start of additional systemic therapy for cGvHD; Cycle = 28 Days

  5. Failure Free Survival (FFS)

    Failure-free survival was defined as the time from date of treatment to any of the following events: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) non-relapse mortality, or iii) addition or initiation of another systemic therapy for cGvHD per Kaplan-Meier estimates. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

    Time frame: From baseline up to 39 cycles; Cycle = 28 Days

  6. Cumulative Incidence of Malignancy Relapse/Recurrence (MR)

    MR was defined as the time from date of treatment assignment to the date of hematologic malignancy relapse/recurrence. Calculated for subjects with underlying hematologic malignant disease. The cumulative incidence (CI) of malignancy relapse/recurrence at 1, 2, 6, 12, 18, 24, 30 and 36 months after start of treatment has been reported. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

    Time frame: From baseline up to 39 cycles; Cycle = 28 Days

  7. Non-relapse Mortality (NRM)

    NRM is defined as the time from date of treatment assignment to date of death not preceded by underlying disease relapse/recurrence calculated for all participants. The cumulative incidence (CI) of non-relapse mortality at 1, 2, 6, 12, 18, 24, 30 and 36 months after start of treatment has been reported. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

    Time frame: From baseline up to 39 cycles; Cycle = 28 Days

  8. Overall Survival (OS)

    OS is defined as the time from the date of treatment assignment to the date of death due to any cause. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

    Time frame: From baseline up to 39 cycles; Cycle = 28 Days

  9. Percentage of Participants With ≥50% Reduction From Baseline in Daily Corticosteroid Dose

    Reduction of at least ≥50% from baseline in daily corticosteroid use by Cycle 7 Day 1 (regardless of reason). As planned in the SAP, this outcome measure is provided for all participants instead of per age groups, for those who received corticosteroids at baseline.

    Time frame: Baseline to Cycle 7 Day 1 (Day 168); Cycle = 28 Days

  10. Percentage of Participants With a Reduction to a Low Dose Corticosteriod

    Reduction to low dose corticosteroids, is defined as the percentage of participants with reduction from baseline in daily corticosteroid dose to methylprednisolone-equivalent steroid dose of ≤ 0.2 mg/kg/day (or equivalent dose of ≤ 0.25 mg/kg/day prednisone or prednisolone). As planned in the SAP, this outcome measure is provided for all participants instead of per age groups, for those who received corticosteroids at baseline.

    Time frame: Baseline to Cycle 7 Day 1 (Day 168); Cycle = 28 Days

  11. Graft Failure

    Reported are the number of participants with graft failure from all age groups together. Graft failure was assessed by donor cell chimerism, defined as initial whole blood or marrow donor chimerism for those who had ≥ 5% donor cell chimerism at baseline. If donor cell chimerism declined to \< 5% on subsequent measurements, graft failure was declared. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

    Time frame: From baseline up to 39 cycles; Cycle = 28 Days

07

Results

Posted Apr 17, 2025

Participant flow

At least 5 evaluable participants per group were needed for the primary analysis in Groups 1, 2 and 3. No minimum number of evaluable participants were needed in Group 4. Disposition and Demographics are presented by age group.

Participant flow — Overall Study
Milestone≥ 12y - < 18y RUX 10mg BID (Group 1)≥ 6y - < 12y RUX 5mg BID (Group 2)≥ 2y - < 6y RUX 4mg/m2 BID (Group 3)
Started22177
Full analysis set22167
Completed treatment353
Discontinued from treatment19114
Participants who received tablets22140
Participants who received liquid027
Completed14104
Not completed873
Withdrew: Death632
Withdrew: Subject decision030
Withdrew: Lost to follow-up200
Withdrew: Guardian decision001
Withdrew: Enrolled but received treatment beyond protocol requirement010

Outcome measures

PrimaryOverall Response Rate (ORR) at Cycle 7 Day 1

ORR is defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response. The response is assessed per National Institute of Health (NIH) consensus criteria and scoring of response was relative to the organ stage at the start of study treatment.

Time frame:
At Cycle 7 Day 1 (Day 168); Cycle = 28 Days
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) at Cycle 7 Day 1
Percentage of participants≥ 12y - < 18y RUX 10mg BID (Group 1)≥ 6y - < 12y RUX 5mg BID (Group 2)≥ 2y - < 6y RUX 4mg/m2 BID (Group 3)All Participants
Overall Response Rate (ORR) at Cycle 7 Day 136.4 (19.6 to 56.1)50.0 (27.9 to 72.1)28.6 (5.3 to 65.9)40.0 (27.7 to 53.3)
SecondaryRuxolitinib Concentrations by Timepoint

Pharmacokinetics (PK) of ruxolitinib by age groups (and formulation tablet vs liquid).

Time frame:
Cycle 1 Day 1: 0.5, 2 and 6 hours post-dose; Pre-dose on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 22, Cycle 3 Day 1, Cycle 5 Day 1 and Cycle 7 Day 1; Cycle = 28 Days
Reported as:
Geometric mean · ug/ml
Ruxolitinib Concentrations by Timepoint
ug/ml≥ 12y - < 18y RUX 10mg BID (Tablet)≥ 6y - < 12y RUX 5mg BID (Tablet)≥ 6y - < 12y RUX 5mg BID (Liquid)≥ 2y - < 6y RUX 4mg/m2 BID (Liquid)
Cycle 1 Day 1: 0.5 hour (hr) (post-dose)60.0 ± 350.732.4 ± 471.978.660.1 ± 98.7
Cycle 1 Day 1: 2 hr (post-dose)112 ± 51.8106 ± 39.277.049.7 ± 30.7
Cycle 1 Day 1: 6hr (post-dose)56.7 ± 73.947.8 ± 164.160.015.3 ± 66.2
Cycle 1 Day 8: 0 hr (pre-dose)16.7 ± 208.310.9 ± 146.53.473.88 ± 152.4
Cycle 1 Day 15: 0 hr (pre-dose)17.8 ± 195.512.9 ± 248.24.14 ± 399.39.43 ± 121.5
Cycle 1 Day 22: 0 hr (pre-dose)20.8 ± 199.511.7 ± 165.44.89 ± 505.210.3 ± 150.4
Cycle 3 Day 1: 0 hr (pre-dose11.4 ± 193.811.3 ± 193.12.66 ± 587.55.56 ± 180.8
Cycle 5 Day 1: 0 hr (pre-dose13.0 ± 176.616.4 ± 470.711.0 ± 83.57.32 ± 102.0
Cycle 7 Day 1: 0 hr (pre-dose14.3 ± 173.710.7 ± 129.95.79 ± 120.14.94 ± 165.9
SecondaryDuration of Response (DOR)

Time from first response until chronic Graft vs. host disease (cGvHD) progression, death, or the date of addition of systemic therapies for cGvHD assessed for responders only based on BOR up to Cycle 7 Day 1. Presented as percentage of participants to still be in response at different time points in months (per Kaplan-Meier estimates). Participants without event will be censored at the date of their last response assessment prior to or at the analysis cut-off date if no events occurred on or before 12 weeks (84 days) after the last GvHD assessment. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

Time frame:
From baseline up to 39 cycles; Cycle = 28 Days
Reported as:
Number · Percentage of participants
Duration of Response (DOR)
Percentage of participantsAll Participants
Month 194.59 (80.07 to 98.62)
Month 286.23 (70.01 to 94.03)
Month 674.24 (56.17 to 85.74)
Month 1263.10 (43.74 to 77.38)
Month 1858.89 (39.23 to 74.12)
Month 2458.89 (39.23 to 74.12)
Month 3058.89 (39.23 to 74.12)
Month 3658.89 (39.23 to 74.12)
SecondaryOverall Response Rate (ORR) at Cycle 4 Day 1

ORR is defined as the percentage of participants demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or non-response. The response is assessed per National Institute of Health (NIH) consensus criteria and scoring of response will be relative to the organ stage at the start of study treatment at Cycle 4 Day 1.

Time frame:
At Cycle 4 Day 1 (Day 84); Cycle = 28 Days
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) at Cycle 4 Day 1
Percentage of participants≥ 12y - < 18y RUX 10mg BID (Group 1)≥ 6y - < 12y RUX 5mg BID (Group 2)≥ 2y - < 6y RUX 4mg/m2 BID (Group 3)All Participants
Overall Response Rate (ORR) at Cycle 4 Day 154.5 (35.3 to 72.9)62.5 (39.1 to 82.2)42.9 (12.9 to 77.5)55.6 (42.3 to 68.3)
SecondaryBest Overall Response (BOR)

Percentage of participants who achieved overall response (complete response (CR) or partial response (PR)) at any time point until Cycle 7 Day 1 or the start of additional systemic therapy for chronic GvHD.

Time frame:
Until Cycle 7 Day 1 (Day 168) or the start of additional systemic therapy for cGvHD; Cycle = 28 Days
Reported as:
Number · Percentage of participants
Best Overall Response (BOR)
Percentage of participants≥ 12y - < 18y RUX 10mg BID (Group 1)≥ 6y - < 12y RUX 5mg BID (Group 2)≥ 2y - < 6y RUX 4mg/m2 BID (Group 3)All Participants
Best Overall Response (BOR)81.8 (63.1 to 93.5)81.3 (58.3 to 94.7)85.7 (47.9 to 99.3)82.2 (70.2 to 90.8)
SecondaryFailure Free Survival (FFS)

Failure-free survival was defined as the time from date of treatment to any of the following events: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) non-relapse mortality, or iii) addition or initiation of another systemic therapy for cGvHD per Kaplan-Meier estimates. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

Time frame:
From baseline up to 39 cycles; Cycle = 28 Days
Reported as:
Number · Percentage of participants
Failure Free Survival (FFS)
Percentage of participantsAll Participants
Month 191.11 (78.03 to 96.57)
Month 284.44 (70.12 to 92.26)
Month 668.89 (53.20 to 80.25)
Month 1264.44 (48.67 to 76.48)
Month 1857.78 (42.11 to 70.61)
Month 2457.78 (42.11 to 70.61)
Month 3057.78 (42.11 to 70.61)
Month 3657.78 (42.11 to 70.61)
SecondaryCumulative Incidence of Malignancy Relapse/Recurrence (MR)

MR was defined as the time from date of treatment assignment to the date of hematologic malignancy relapse/recurrence. Calculated for subjects with underlying hematologic malignant disease. The cumulative incidence (CI) of malignancy relapse/recurrence at 1, 2, 6, 12, 18, 24, 30 and 36 months after start of treatment has been reported. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

Time frame:
From baseline up to 39 cycles; Cycle = 28 Days
Reported as:
Number · Percentage of participants
Cumulative Incidence of Malignancy Relapse/Recurrence (MR)
Percentage of participantsAll Participants
Month 13.33 (0.23 to 14.80)
Month 210.00 (2.47 to 23.88)
Month 610.00 (2.47 to 23.88)
Month 1210.00 (2.47 to 23.88)
Month 1810.00 (2.47 to 23.88)
Month 2410.00 (2.47 to 23.88)
Month 3010.00 (2.47 to 23.88)
Month 3610.00 (2.47 to 23.88)
SecondaryNon-relapse Mortality (NRM)

NRM is defined as the time from date of treatment assignment to date of death not preceded by underlying disease relapse/recurrence calculated for all participants. The cumulative incidence (CI) of non-relapse mortality at 1, 2, 6, 12, 18, 24, 30 and 36 months after start of treatment has been reported. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

Time frame:
From baseline up to 39 cycles; Cycle = 28 Days
Reported as:
Number · Percentage of participants
Non-relapse Mortality (NRM)
Percentage of participantsAll Participants
Month 12.22 (0.17 to 10.28)
Month 22.22 (0.17 to 10.28)
Month 66.67 (1.70 to 16.53)
Month 1213.33 (5.34 to 25.02)
Month 1817.78 (8.23 to 30.28)
Month 2420.07 (9.80 to 32.93)
Month 3020.07 (9.80 to 32.93)
Month 3620.07 (9.80 to 32.93)
SecondaryOverall Survival (OS)

OS is defined as the time from the date of treatment assignment to the date of death due to any cause. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

Time frame:
From baseline up to 39 cycles; Cycle = 28 Days
Reported as:
Number · survival probability in percentage
Overall Survival (OS)
survival probability in percentageAll Participants
Month 197.78 (85.25 to 99.68)
Month 297.78 (85.25 to 99.68)
Month 691.06 (77.90 to 96.55)
Month 1284.23 (69.73 to 92.15)
Month 1879.67 (64.57 to 88.87)
Month 2477.33 (61.94 to 87.11)
Month 3077.33 (61.94 to 87.11)
Month 3674.91 (59.26 to 85.26)
SecondaryPercentage of Participants With ≥50% Reduction From Baseline in Daily Corticosteroid Dose

Reduction of at least ≥50% from baseline in daily corticosteroid use by Cycle 7 Day 1 (regardless of reason). As planned in the SAP, this outcome measure is provided for all participants instead of per age groups, for those who received corticosteroids at baseline.

Time frame:
Baseline to Cycle 7 Day 1 (Day 168); Cycle = 28 Days
Reported as:
Number · Percentage of participants
Percentage of Participants With ≥50% Reduction From Baseline in Daily Corticosteroid Dose
Percentage of participantsAll Participants
Percentage of Participants With ≥50% Reduction From Baseline in Daily Corticosteroid Dose75.0
SecondaryPercentage of Participants With a Reduction to a Low Dose Corticosteriod

Reduction to low dose corticosteroids, is defined as the percentage of participants with reduction from baseline in daily corticosteroid dose to methylprednisolone-equivalent steroid dose of ≤ 0.2 mg/kg/day (or equivalent dose of ≤ 0.25 mg/kg/day prednisone or prednisolone). As planned in the SAP, this outcome measure is provided for all participants instead of per age groups, for those who received corticosteroids at baseline.

Time frame:
Baseline to Cycle 7 Day 1 (Day 168); Cycle = 28 Days
Reported as:
Number · Percentage of participants
Percentage of Participants With a Reduction to a Low Dose Corticosteriod
Percentage of participantsAll Participants
Percentage of Participants With a Reduction to a Low Dose Corticosteriod67.5
SecondaryGraft Failure

Reported are the number of participants with graft failure from all age groups together. Graft failure was assessed by donor cell chimerism, defined as initial whole blood or marrow donor chimerism for those who had ≥ 5% donor cell chimerism at baseline. If donor cell chimerism declined to \< 5% on subsequent measurements, graft failure was declared. As planned in the SAP, this outcome measure is provided for all participants instead of per age groups.

Time frame:
From baseline up to 39 cycles; Cycle = 28 Days
Reported as:
Number · Participants
Graft Failure
ParticipantsAll Participants
Graft Failure2

Adverse events

Collected over Adverse events (AEs) and on-treatment deaths were collected from the first dose of study treatment up to 30 days after last dose of study medication. Post-treatment survival follow-up deaths were collected 31 days after last dose of study medication until the end of the study, up to approx. 36 months/39 cycles.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
On-Treatment >=12y - <18y RUX 10mg BID0/22 (0%)15/22 (68.2%)22/22 (100%)
On-Treatment >=6y - <12y RUX 5mg BID2/16 (12.5%)7/16 (43.8%)15/16 (93.8%)
On-Treatment >=2y - <6y RUX 4mg/m2 BID1/7 (14.3%)4/7 (57.1%)7/7 (100%)
On-Treatment - All Participants3/45 (6.7%)26/45 (57.8%)44/45 (97.8%)
Post-Treatment >=12y - <18y RUX 10mg BID6/22 (27.3%)3/22 (13.6%)4/22 (18.2%)
Post-Treatment >=6y - <12y RUX 5mg BID1/16 (6.3%)0/16 (0%)2/16 (12.5%)
Post-Treatment >=2y - <6y RUX 4mg/m2 BID1/7 (14.3%)0/7 (0%)0/7 (0%)
Post-Treatment All Participants8/45 (17.8%)3/45 (6.7%)6/45 (13.3%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventOn-Treatment >=12y - <18y RUX 10mg BIDOn-Treatment >=6y - <12y RUX 5mg BIDOn-Treatment >=2y - <6y RUX 4mg/m2 BIDOn-Treatment - All ParticipantsPost-Treatment >=12y - <18y RUX 10mg BIDPost-Treatment >=6y - <12y RUX 5mg BIDPost-Treatment >=2y - <6y RUX 4mg/m2 BIDPost-Treatment All Participants
Febrile neutropeniaBlood and lymphatic system disorders0/220/161/71/450/220/160/70/45
PyrexiaGeneral disorders2/220/161/73/450/220/160/70/45
Aspergillus infectionInfections and infestations0/220/161/71/450/220/160/70/45
Human bocavirus infectionInfections and infestations0/220/161/71/450/220/160/70/45
Parainfluenzae virus infectionInfections and infestations0/220/161/71/450/220/160/70/45
Pneumonia viralInfections and infestations0/220/161/71/450/220/160/70/45
Rhinovirus infectionInfections and infestations0/220/161/71/450/220/160/70/45
Tooth infectionInfections and infestations0/220/161/71/450/220/160/70/45
Upper respiratory tract infectionInfections and infestations0/220/161/71/450/220/160/70/45
COVID-19Infections and infestations2/220/160/72/451/220/160/71/45
Most frequent other events
Showing 10 of 135
Most frequent other events
EventOn-Treatment >=12y - <18y RUX 10mg BIDOn-Treatment >=6y - <12y RUX 5mg BIDOn-Treatment >=2y - <6y RUX 4mg/m2 BIDOn-Treatment - All ParticipantsPost-Treatment >=12y - <18y RUX 10mg BIDPost-Treatment >=6y - <12y RUX 5mg BIDPost-Treatment >=2y - <6y RUX 4mg/m2 BIDPost-Treatment All Participants
Upper respiratory tract infectionInfections and infestations1/224/164/79/450/220/160/70/45
AnaemiaBlood and lymphatic system disorders7/222/162/711/450/220/160/70/45
NeutropeniaBlood and lymphatic system disorders2/224/162/78/450/220/160/70/45
COVID-19Infections and infestations4/223/162/79/450/220/160/70/45
Neutrophil count decreasedInvestigations5/222/162/79/450/220/160/70/45
PyrexiaGeneral disorders3/224/160/77/450/220/160/70/45
Platelet count decreasedInvestigations5/222/160/77/451/220/160/71/45
HeadacheNervous system disorders5/222/160/77/451/220/160/71/45
NasopharyngitisInfections and infestations1/223/161/75/450/220/160/70/45
CoughRespiratory, thoracic and mediastinal disorders3/223/160/76/451/220/160/71/45

Baseline characteristics

Full Analysis Set (FAS) comprised all subjects to whom study treatment has been assigned and who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(months)≥ 12y - < 18y RUX 10mg BID (Group 1)≥ 6y - < 12y RUX 5mg BID (Group 2)≥ 2y - < 6y RUX 4mg/m2 BID (Group 3)Total
Mean175.2 ± 20.0599.3 ± 18.3947.1 ± 15.08128.3 ± 52.86
Sex: Female, Male
Sex: Female, Male(Participants)≥ 12y - < 18y RUX 10mg BID (Group 1)≥ 6y - < 12y RUX 5mg BID (Group 2)≥ 2y - < 6y RUX 4mg/m2 BID (Group 3)Total
Female77216
Male159529
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)≥ 12y - < 18y RUX 10mg BID (Group 1)≥ 6y - < 12y RUX 5mg BID (Group 2)≥ 2y - < 6y RUX 4mg/m2 BID (Group 3)Total
White810321
Black or African American0101
Asian145423
08

Study locations

21 sites
  • Novartis Investigative Site
    São Paulo, 04039 001, Brazil
  • Novartis Investigative Site
    Toronto, Ontario M5G 1X8, Canada
  • Novartis Investigative Site
    Prague, 150 06, Czechia
  • Novartis Investigative Site
    Tamil Nadu, Chennai 600035, India
  • Novartis Investigative Site
    Pune, Maharashtra 411004, India
  • Novartis Investigative Site
    Bangalore, 560099, India
  • Novartis Investigative Site
    Delhi, 110 085, India
  • Novartis Investigative Site
    Roma, RM 00165, Italy
  • Novartis Investigative Site
    Nagoya, Aichi-ken 466 8560, Japan
  • Novartis Investigative Site
    Saitama, 330 8777, Japan
  • Novartis Investigative Site
    Saint Petersburg, 197022, Russia
  • Novartis Investigative Site
    Bratislava, 833 40, Slovakia
  • Novartis Investigative Site
    Seoul, 03080, South Korea
  • Novartis Investigative Site
    Seoul, 05505, South Korea
  • Novartis Investigative Site
    Barcelona, Catalonia 08035, Spain
  • Novartis Investigative Site
    Zurich, CH - 8032, Switzerland
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Adana, 1330, Turkey (Türkiye)
  • Novartis Investigative Site
    Antalya, 07000, Turkey (Türkiye)
  • Novartis Investigative Site
    Antalya, 07070, Turkey (Türkiye)
09

References and documents

Publications

  • Locatelli F, Antmen B, Kang HJ, Koh K, Takahashi Y, Kupesiz A, Dias Matos MGA, Chopra Y, Bhat S, Im HJ, Gungor T, Lu MY, Stefanelli T, Rosko C, St Pierre A, Burock K, Smith Y, Sinclair K, Diaz-de-Heredia C. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. Lancet Haematol. 2024 Aug;11(8):e580-e592. doi: 10.1016/S2352-3026(24)00174-1. Epub 2024 Jul 10. PubMed 39002551 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Feb 2022, 21 months.

Results were first posted in Apr 2025, 3 years 1 month after primary completion.

Of 102 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2018
First posted
Dec 12, 2018
StartActual
May 20, 2020
Primary completionActual
Feb 25, 2022
CompletionActual
Aug 26, 2024
Results first posted
Apr 17, 2025
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03774082
Responsible party
Sponsor
First posted
Dec 12, 2018
Start date
May 20, 2020
Primary completion
Feb 25, 2022
Completion
Aug 26, 2024
Results posted
Apr 17, 2025
Last update
Dec 11, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion